SOUTH SAN FRANCISCO, Calif., Nov. 19, 2018 /PRNewswire-PRWeb/ -- American Pharmaceutical Review, the leading review of
The documentary features commentary and outlook from key opinion leaders representing regulatory, industry, consulting and technology providers who offer their thoughts and outlook on the current state of microbiology contamination control, industry challenges, and the future outlook for this critical industry topic.
"Biopharmaceuticals have traditionally been produced in sterile environments as a means to ensure product quality and to reduce failed batches. In addition, as more scrutiny is put on the manufacture of all types of products, oral solid dosage manufacturers are investing in equipment, technologies and expertise to move their processes towards a cleaner manufacturing environment." says Mike Auerbach, Editor In Chief, American Pharmaceutical Review. "How do both sides of the industry ensure their products are produced in clean modern facilities? What are the latest tools, techniques, services and best practices to manufacture the highest quality products while minimizing or eliminating the possibility of batch failures or regulatory intervention? Through this documentary we explore this topic in depth and provide those who are dealing with microbiology issues as many answers as possible."
The markets for both biopharmaceutical and oral solid dosage forms are expected to grow in the coming years. According to Research and Markets latest report "Global Biopharmaceutical Manufacturing Market Report 2017-2021", "The efficacy and safety of biopharmaceuticals, coupled with their ability to address previously untreatable conditions, allows healthcare companies to command higher prices and margins for these drugs. Driven by their numerous advantages over conventional drugs, biopharmaceuticals today represent a big opportunity and represent more than 20% of the total global pharmaceutical sales. The current annual growth rate of biopharmaceuticals is also double that of conventional drugs, and growth is expected to remain robust for the foreseeable future."
According to Future Market Insights, the global oral solid dosage pharmaceutical formulation market is expected to grow from $493.2 billion in 2017 to $926.3 billion by the end of 2027. Facilitated by a global increase in the geriatric population, particularly across leading economies such as Japan and the U.S., coupled with the development of functional excipients that exhibit superior properties such as flow-ability, the global pharma excipients market is expected to create impressive opportunities for manufacturers to capitalize on in the near future.
For more information on this American Pharmaceutical Review documentary on Clean Facilities of the Future: Advanced Microbiology Technologies for Cleaner Facilities and Purer Products please visit https://www.americanpharmaceuticalreview.com/Clean-Facility-of-the-Future/.
About American Pharmaceutical Review American Pharmaceutical Review is the leading journal for business and technology in the pharmaceutical industry. Offering unbiased editorial on drug delivery, information technology, research & development, analytical development and control, equipment and facility manufacturing and regulatory affairs, American Pharmaceutical Review keeps its users fully abreast of the latest trends and developments in the process of pharmaceutical manufacturing. http://www.americanpharmaceuticalreview.com.
SOURCE American Pharmaceutical Review
Subscribe to our Free Newsletters!